Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Qiagen ( (QGEN) ) has shared an update.
QIAGEN has disclosed a managers’ transaction involving Chief Financial Officer and managing board member Roland Sackers, in line with EU Market Abuse Regulation requirements. The filing details changes in his equity-based compensation, specifically performance stock units and resulting common shares.
The company reported the release of 50,792 performance stock units granted in February 2023, the cancellation of 16,931 units and the net settlement into 26,660 common shares after withholding a portion to cover taxes and related expenses. The transaction, executed outside a trading venue on February 28, 2026, reflects ongoing use of share-based incentive programs that align management compensation with shareholder interests and QIAGEN’s share price performance.
The most recent analyst rating on (QGEN) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. is a Netherlands-based life sciences company whose shares trade in Frankfurt, on several German regional exchanges, and internationally on the NYSE, SIX and BX Swiss. The company provides sample and assay technologies for molecular diagnostics, applied testing, academic research and pharmaceutical development, serving laboratories and healthcare customers worldwide.
Average Trading Volume: 2,173,009
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.1B
For detailed information about QGEN stock, go to TipRanks’ Stock Analysis page.